Histogen, Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Histogen is a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body. The Company’s innovative technology utilizes cell conditioned media (CCM) and extracellular matrix (hECM) materials produced by hypoxia-induced multipotent cells to develop therapeutic products that address underserved, multi-billion US dollar global markets.

Histogen is currently developing three key products in the areas of dermatology and orthopedics. In addition to advancing HST001, its Hair Stimulating Complex (HSC), into a Phase 1b trial for male pattern hair loss, Histogen’s clinical pipeline includes two promising clinical candidates utilizing the Company’s proprietary hECM material in distinct formulations. Histogen anticipates that these product candidates for hair growth, dermal filler and joint cartilage regeneration will enter clinical trials in early 2020.
Ticker:
HSTO
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
HST 001 - Hair Stimulating Complex (HSC)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
President and CEO
Histogen Inc.